Hikma 'thrilled' by US injectables contract win

Hikma Pharmaceutical on Thursday confirmed the signing of an exclusive license, supply and distribution agreement with Beijing Sciecure Pharmaceutical Co.

The new agreement provides Hikma with exclusive rights to sell one of Sciecure's niche injectable anti-viral medicines across the US for a minimum of eight years, with an option to extend this partnership for an additional two years.

Daniel Motto, Hikma's executive vice president of commercial and business development, said: "We are thrilled to partner with Sciecure, an innovative and vertically integrated company capable of producing high-quality products across the pharmaceutical spectrum from API to finished doses."

A statement from the FTSE 250-listed company said that Sciecure expects to file its niche injectable anti-viral medicine products for approval with the US Food and Drug Administration in early 2019.

"Our partnership with Sciecure is another example of how Hikma is continuing to expand its pipeline, targeting both niche products and high-volume opportunities, in order to offer a broad portfolio of high-quality medicines to US patients, physicians and hospitals," said Motto.

Hikma Pharmaceutical’s shares were down 1.88% at 1,673.00p at 1121 GMT.